Yonsei Med J.  2012 Jul;53(4):759-764. 10.3349/ymj.2012.53.4.759.

Anti-Cyclic Citrullinated Peptide Antibodies and Joint Involvement in Behcet's Disease

• Cho SB
• Lee JH
• Ahn KJ
• Bae BG
• Kim T
• Park YB
• Lee SK
• Lee KH
• Bang D

• KMID: 1716875
• DOI: http://doi.org/10.3349/ymj.2012.53.4.759

Abstract

PURPOSE
We aimed to determine the prevalence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in a large group of Korean patients with Behcet's disease (BD), with and without joint involvement, and to compare these findings with the prevalences of anti-CCP antibodies in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
MATERIALS AND METHODS
We tested 189 patients with BD, 105 with RA, and 36 with SLE for anti-CCP antibodies and IgM rheumatoid factor in serum. We reviewed the medical records of patients with BD to investigate their personal and clinical characteristics as well as their laboratory test results.
RESULTS
Anti-CCP antibodies were detected in seven of the 189 BD patients (3.7%), at a mean titer of 30.6+/-44.4 U/mL, in 86 of the 105 RA patients (81.9%) with a mean titer of 198.8+/-205.7 U/mL, and in nine of the 36 SLE patients (25%) with a mean titer of 180.4+/-113.9 U/mL. One of the seven anti-CCP-positive BD patients fulfilled the diagnostic criteria for both BD and RA. Five of the seven anti-CCP-positive BD patients (71.4%) had polyarticular joint involvement, and the other two patients (28.6%) had oligoarticular involvement.
CONCLUSION
We determined the prevalence of anti-CCP antibodies in a large group of Korean BD patients with and without joint involvement. Negative anti-CCP test in patients with BD may help to differentiate BD from RA and SLE, all of which present with similar clinical features.

Keyword

Behcet's disease; joint involvement; anti-cyclic citrullinated peptide antibody; rheumatoid factor; systemic lupus erythematosus; rheumatoid arthritis

MeSH Terms

Adolescent
Adult
Aged
Antibodies/*blood
Arthritis, Rheumatoid/blood/immunology
Behcet Syndrome/*blood/immunology
Child
Female
Humans
Lupus Erythematosus, Systemic/blood/immunology
Male
Middle Aged
Peptides, Cyclic/*immunology
Young Adult

Reference

1. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008. 58:3009–3019.

2. Generini S, Steiner G, Miniati I, Conforti ML, Guiducci S, Skriner K, et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford). 2009. 48:920–925.

3. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007. 146:797–808.

4. Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus. 2009. 18:713–717.

5. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Delgado JF, Martínez-Gómez X, Trallero-Araguás E, et al. Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2009. 48:676–679.

6. Koca SS, Akbulut H, Dag S, Artas H, Isik A. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease. Tohoku J Exp Med. 2007. 213:297–304.

7. Rojas-Serrano J, Burgos-Vargas R, Pérez LL, García CG, Moctezuma F, Vázquez-Mellado J. Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Rheumatol. 2009. 28:1135–1139.

8. Uyanik A, Albayrak F, Uyanik MH, Dursun H, Keles M, Cetinkaya R. Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. Rheumatol Int. 2010. 30:467–471.

9. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol. 2005. 34:359–366.

10. Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, et al. Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int. 2007. 27:1125–1130.

11. Kogure T, Tatsumi T, Fujinaga H, Niizawa A, Terasawa K. Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies. Mediators Inflamm. 2007. 2007:12367.

12. Köseoğlu HK, Yücetürk TE, Bayraktar N, Tufan MA, Gencer M, Yücel AE. Anti-CCP antibodies in Behçet's disease with or without articular involvement. New J Med. 2011. 28:92–94.

13. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990. 335:1078–1080.

14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997. 40:1725.

15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982. 25:1271–1277.

16. Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behçet's disease. Yonsei Med J. 2012. 53:35–42.

17. Gharibdoost F, Davatchi F, Shahram F. Godeau P, Wechsler B, editors. Clinical manifestations of Behçet's disease in iran analysis of 2,176 cases. Behçet's disease. 1993. 1st ed. Amsterdam: Elsevier Science Publishers;153–158.

18. Dilsen N, Konice M, Aral O. Godeau P, Wechsler B, editors. Risk factors for vital organ involvement in Behçet's disease. Behçet's disease. 1993. 1st ed. Amsterdam: Elsevier Science Publishers;165–169.

19. Prokaeva T, Madanat W, Yermakova N, Alekberova Z. Godeau P, Wechsler B, editors. Sex dimorphism of Behçet's disease. Behçet's disease. 1993. 1st ed. Amsterdam: Elsevier Science Publishers;219–221.

20. Zouboulis CHC, Djawari D, Kirch W. Godeau P, Wechsler B, editors. Adamantiades-Behçet's disease in Germany. Behçet's disease. 1993. 1st ed. Amsterdam: Elsevier Science Publishers;193–196.

21. Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdoğan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis. 1984. 43:783–789.

22. Yurdakul S, Yazici H, Tüzün Y, Pazarli H, Yalçin B, Altaç M, et al. The arthritis of Behçet's disease: a prospective study. Ann Rheum Dis. 1983. 42:505–515.

23. Bang D, Lee JH, Lee ES, Lee S, Choi JS, Kim YK, et al. Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter study. J Korean Med Sci. 2001. 16:615–618.

24. Damián-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus. 2008. 17:300–304.

25. Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol. 2008. 35:77–83.

26. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther. 2005. 7:R1421–R1429.

27. Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum. 2003. 48:2025–2035.

28. Lee JH, Oh MH, Lee HT, Jang JY, Bang DS, Lee KH. The cross-reactivity of anti human α-enolase antibody in the sera of Behçet's disease patients to Streptococcus sanguis antigen. Korean J Investig Dermatol. 2005. 12:83–92.

29. Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci. 2005. 20:473–478.